|Bid||13.10 x 34100|
|Ask||17.90 x 900|
|Day's Range||15.20 - 16.27|
|52 Week Range||9.70 - 27.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.67|
RICHMOND, Calif. , Aug. 10, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that management will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference ...
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
RICHMOND, Calif., Aug. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer Inc. for the development and commercialization of potential gene therapy programs for Hemophilia A. The Alta study is an open-label, dose-ranging clinical trial designed to assess the safety and tolerability of SB-525 in up to 20 adult subjects with severe Hemophilia A. To date, five patients have been treated at three dose levels.
Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial Evaluating SB-525 Gene Therapy for Hemophilia A Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time ...
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Sangamo Therapeutics, Inc. (NASDAQ: SGMO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 5:00 PM Eastern ...
RICHMOND, Calif. , Aug. 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its second quarter 2018 financial results after the market closes ...
RICHMOND, Calif., July 31, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that preliminary safety and efficacy data from the CHAMPIONS Study, a Phase 1/2 clinical trial ...
RICHMOND, Calif., July 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that the Company will host a webcast to review mucopolysaccharidosis Type II (MPS II, or Hunter syndrome) disease biology, standard of care treatment options, and scientific rationale for the development of SB-913, Sangamo's investigational in vivo genome editing treatment for MPS II. The webcast is scheduled for 2 p.m. Eastern Time on Wednesday, August 1, 2018. In late summer Sangamo plans to present preliminary data from the Phase 1/2 clinical trial evaluating SB-913 for MPS II ("the CHAMPIONS study"). This press release contains forward-looking statements regarding Sangamo's current expectations.
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. TxCell’s expertise in regulatory T-cell (Treg) development is meant to accelerate Sangamo’s clinical evaluation of CAR-Treg therapies to support organ transplants and treat autoimmune diseases like Crohn’s disease and multiple sclerosis. "We believe CAR-Treg therapies will prove to be as exciting for immunology as CAR-T has been for oncology,” Sangamo CEO Sandy Macrae said in a press release.
Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.
RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) and TxCell S.A. (TXCL.PA) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of €2.58 per share in cash, or approximately €72 million, on a debt-free and cash-free basis. Subject to satisfaction of closing conditions (including in particular those relating to regulations governing foreign investments in France), Sangamo expects to complete the transaction in the fourth quarter of 2018.
RICHMOND, Calif., July 13, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced that Michael Holmes, Ph.D., Senior Vice President and Chief Technology Officer, will resign from the Company effective July 20th to pursue an opportunity with a startup biotech company. Edward Rebar, Ph.D., has been named Senior Vice President and Chief Technology Officer, effective immediately. "We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo.
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / Many medical companies throughout the world are pinning their hopes for miracle cures on stem cell therapies. Because of the ability of stem cells to differentiate ...
Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...
RICHMOND, Calif., June 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the appointment of Dr. Karen Smith, an accomplished drug development executive, to the Company's Board of Directors. "Karen's extensive experience in drug development, registration and commercialization will benefit Sangamo tremendously, and I'm pleased to welcome her to our board," said Dr. Sandy Macrae, Chief Executive Officer of Sangamo. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia.